Vizora日本語

BrightPath BiotherapeuticsBrightPath Biotherapeutics Co., Ltd.4594東証グロース医薬品FY ending Mar 2025, non-consolidated, J-GAAP

BrightPath Biotherapeutics FY ending Mar 2021 results

BrightPath Biotherapeutics brought in ¥2.5M in revenue.

It lost about ¥69201 for every ¥100 of sales at the operating level.

Revenue changed -77.8% from the prior year.

What changed from last year

FY ending Mar 2020 → FY ending Mar 2021

Revenue
-77.8%¥11.3M → ¥2.5M
Gross profit
-80.1%¥6.8M → ¥1.4M
Operating income
Loss-¥1.83B → -¥1.73B
Operating cash flow
Loss-¥1.78B → -¥1.77B
Free cash flow
Loss-¥1.89B → -¥1.81B

Where the money goes

FY ending Mar 2020 → FY ending Mar 2021

Where ¥100 of sales goes

For every ¥100 BrightPath Biotherapeutics sells, how much goes where, and how much is kept.

FY ending Mar 2021
Cost of sales
¥46
SG&A
¥69255
Operating loss
¥69201
Net loss
¥68675

Annual margin trends

Gross margin54.2%
FY ending Mar 2020: 60.5%60.5%FY ending Mar 2021: 54.2%54.2%FY20FY21
Operating margin-69201.4%
FY ending Mar 2020: -16171.2%-16171.2%FY ending Mar 2021: -69201.4%-69201.4%FY20FY21
Net margin-68675.5%
FY ending Mar 2020: -16440.5%-16440.5%FY ending Mar 2021: -68675.5%-68675.5%FY20FY21

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (5)

  • EDINET (FSA Japan)

    有価証券報告書－第22期(2024/04/01－2025/03/31)

    ID S100VZBU2025-06-19Open

  • EDINET (FSA Japan)

    有価証券報告書－第21期(2023/04/01－2024/03/31)

    ID S100TP5I2024-06-21Open

  • EDINET (FSA Japan)

    有価証券報告書－第20期(2022/04/01－2023/03/31)

    ID S100QKJ22023-06-22Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第19期(令和3年4月1日－令和4年3月31日)

    ID S100PTK62022-12-19Open

  • EDINET (FSA Japan)

    有価証券報告書－第18期(令和2年4月1日－令和3年3月31日)

    ID S100LQ6N2021-06-25Open

Extracted from XBRL: 39 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image